Trial Profile
Yervoy Postmarketing Surveillance for Patients in Japan With Unresectable, Malignant Melanoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Mar 2022
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 11 Feb 2022 Status changed from recruiting to completed.
- 18 Sep 2018 Planned End Date changed from 31 Aug 2018 to 31 Dec 2020.
- 18 Sep 2018 Planned primary completion date changed from 31 Aug 2018 to 24 Jun 2020.